Diagnostic Microbiology & Infectious Disease
Volume 54, Issue 1 , Pages 63-71 , January 2006

Contemporary antimicrobial activity of triple antibiotic ointment: a multiphased study of recent clinical isolates in the United States and Australia

  • Ronald N. Jones

      Affiliations

    • JMI Laboratories, North Liberty, IA 52317, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-319-665-3370; fax: +1-319-665-3371.
    • ,
  • Qing Li

      Affiliations

    • Pfizer Consumer Healthcare, Morris Plains, NJ 07950, USA
    • ,
  • Bruce Kohut

      Affiliations

    • Pfizer Consumer Healthcare, Morris Plains, NJ 07950, USA
    • ,
  • Douglas J. Biedenbach

      Affiliations

    • JMI Laboratories, North Liberty, IA 52317, USA
    • ,
  • Jan Bell

      Affiliations

    • Women's and Children's Hospital, Adelaide, Australia
    • ,
  • John D. Turnidge

      Affiliations

    • Women's and Children's Hospital, Adelaide, Australia

Received 9 June 2005 ,Accepted 9 August 2005.

References 

  1. Arkwright PD, Daniel TO, Sanyal D, David TJ, Patel L. Age-related prevalence and antibiotic resistance of pathogenic staphylococci and streptococci in children with infected atopic dermatitis at a single-specialty center. Arch. Dermatol. 2002;138:939–941
  2. Barry AL. The antimicrobic susceptibility test: principles and practices. Philadelphia: Lea & Febiger; 1976;
  3. Berger RS, Pappert AS, Van Zile PS, Cetnarowski WE. A newly formulated topical triple-antibiotic ointment minimizes scarring. Cutis. 2000;65:401–404
  4. Bertino JS. Intranasal mupirocin for outbreaks of methicillin-resistant Staphylococcus aureus. Am. J. Health Syst. Pharm. 1997;54:2185–2191
  5. Chaves F, Garcia-Martinez J, de Miguel S, Otero JR. Molecular characterization of resistance to mupirocin in methicillin-susceptible and -resistant isolates of Staphylococcus aureus from nasal samples. Clin. Microbiol. 2004;42:822–824
  6. Cetnarowski W, Gabriel S. Comparison of two neosporin ointment formulations on the time to healing of human dermabrasion wounds. Clin. Pharmacol. Ther. 1998;63:213
  7. Clinical and Laboratory Standards Institute . Performance standards for antimicrobial susceptibility testing. Document M100-S15 Wayne, PA: CLSI; 2005;
  8. Conly JM, Johnston BL. Mupirocin—are in danger of loosing it?. Can. J. Infect. Dis. 2002;13:1–5
  9. Cookson BD. The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. J. Antimicrob. Chemother. 1998;41:11–18
  10. Coombs G, Malkowski M, Pearson J, Community MRSA in Australia . In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27–30, San Diego, CA. 2002;
  11. Desphande LM, Fix AM, Pfaller MA, Jones RN for the SENTRY Antimicrobial Surveillance Program Participants Group. Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods. Diagn. Microbiol. Infect. Dis. 2002;42:283–290
  12. Dire DJ, Coppola M, Dwyer DA, Lorette JJ, Karr JL. Prospective evaluation of topical antibiotics for preventing infections in uncomplicated soft-tissue wounds repaired in the ED. Acad. Emerg. Med. 1995;2:4–10
  13. Fuchs PC, Jones RN, Barry AL. Interpretive criteria for disk diffusion susceptibility testing of mupirocin, a topical antibiotic. J. Clin. Microbiol. 1990;28:608–609
  14. Fuller AT, Mellows G, Woolford M. Pseudomonic acid: an antibiotic produced by Pseudomonas fluorescens. Nature. 1971;234:416–417
  15. Fung S, O'Grady S, Kennedy C, Dedier H, Campbell I, Conly J. The utility of polysporin ointment in the eradication of methicillin-resistant Staphylococcus aureus colonization: a pilot study. Infect. Control. Hosp. Epidemiol. 2000;21:653–655
  16. Gales AC, Andrade SS, Sader HS, Jones RN. Activity of mupirocin and 14 additional antibiotics against staphylococci isolated from Latin American hospitals: report from the SENTRY Antimicrobial Surveillance Program. J. Chemother. 2004;16:323–328
  17. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J. Clin. Microbiol. 2001;39:183–190
  18. Giacometti A, Cirioni O, Schimizzi AM, Del Prete MS, Barchiesi F, D'Errico MM, et al. Epidemiology and microbiology of surgical wound infections. J. Clin. Microbiol. 2000;38:918–922
  19. GlaxoSmithKline . Bactroban nasal package insert. Research Triangle Park, NC: GSK; 2001;http://www.gsk.com/products/bactronban.us.htm.
  20. Hendley JO, Ashe KM. Effect of topical antimicrobial treatment on aerobic bacteria in the stratum corneum of human skin. Antimicrob. Agents Chemother. 1991;35:627–631
  21. Hendley JO, Ashe KM. Eradication of resident bacteria of normal human skin by antimicrobial ointment. Antimicrob. Agents Chemother. 2003;47:1988–1990
  22. Jones RN, Milazzo J, Seidlin M. Ofloxacin otic solution for therapy of otitis externa in children and adults. Arch. Otolaryngol. Head Neck Surg. 1997;123:1193–1200
  23. Kirby JT, Mutnick AH, Jones RN, Biedenbach DJ, Pfaller MA for the SENTRY Participants Group. Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000). Diagn. Microbiol. Infect Dis. 2002;43:303–309
  24. Kresken M, Hafner D, Schmitz F-J, Wichelhaus TA on behalf of the Working Group for Antimicrobial Resistance of the Paul-Ehrlich-Society for Chemotherapy. Prevalence of mupirocin resistance in clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis: results of the Antimicrobial Resistance Surveillance Study of the Paul-Ehrlich-Society for Chemotherapy, 2001. Int. J. Antimicrob. Agents. 2004;23:577–581
  25. Leyden JJ, Kligman AM. Contact dermatitis to neomycin sulfate. JAMA. 1979;242:1276–1278
  26. Leski TA, Gniadkowski M, Skoczynska A, Stefaniuk E, Trzcinski K, Hryniewicz W. Outbreak of mupirocin-resistant staphylococci in a hospital in Warsaw, Poland, due to plasmid transmission and clonal spread of several strains. J. Clin. Microbiol. 1999;37:2781–2788
  27. Members of the SFM Antibiogram Committee . Comite de l'Antibiogramme de la Societe Francaise de Microbiologie. Report 2003. Int. J. Antimicrob. Agents. 2003;21:364–391
  28. Multiple authors . Update on topical antibiotic therapy: changing antibiotic susceptibility patterns and clinical applications. Cutis. 2003;71:1–24
  29. National Committee for Clinical Laboratory Standards . Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. In: Approved standard. 6th ed.. Wayne, PA: NCCLS; 2003;(Document M7-A6)
  30. Pezzati M, Biagioli EC, Martelli E, Gambi B, Biagiotti R, Rubaltelli FF. Umbilical cord care: the effect of eight different cord-care regiments on cord separation time and other outcomes. Biol. Neonate. 2002;81:38–44
  31. Poupard JA. Update on mupirocin resistance. J. Chemother. 1995;7(Suppl 3):71–74
  32. Prystowsky SD, Allen AM, Smith RW, Nonomura JH, Odom RB, Akers WA. Allergic contact hypersensitivity to nickel, neomycin, ethylenediamine, and benzocaine: relationships between age, sex, history of exposure, and reactivity to standard patch tests and use tests in a general population. Arch. Dermatol. 1979;115:959–962
  33. Prystowsky SD, Nonomura JH, Smith RW, Allen AM. Allergic hypersensitivity to neomycin: relationship between patch test reactions and “use” tests. Arch. Dermatol. 1979;115:713–715
  34. Sander R. Otitis externa: a practical guide to treatment and prevention. Am. Fam. Physician. 2001;63:927–936
  35. Santos KRN, Fonseca LS, Gontijo Filho PP. Emergence of high-level mupirocin resistance in methicillin-resistant Staphylococcus aureus isolated from Brazilian university hospitals. Infect. Control Hosp. Epidemiol. 1996;17:813–816
  36. Schmitz FJ, Lindenlauf E, Hofmann B, Fluit AD, Verhoef J, Heinz HP, et al. The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals. J. Antimicrob. Chemother. 1998;42:489–495
  37. Slocombe B, Perry C. The antimicrobial activity of mupirocin—an update on resistance. J. Hosp. Infect. 1991;19(Suppl B):19–25
  38. Tacconelli E, Carmeli Y, Aizer A, Ferreira G, Foreman MG, D'Agata EMC. Mupirocin prophylaxis to prevent Staphylococcus aureus infection in patients undergoing dialysis: a meta-analysis. Clin. Infect. Dis. 2003;37:1629–1638
  39. Terpenning MS, Bradley SF, Wan JY, Chenoweth CE, Jorgensen KA, Kauffman CA. Colonization and infection with antibiotic-resistant bacteria in a long-term care facility. J. Am. Geriatr. Soc. 1994;42:1062–1069
  40. Upton A, Lang S, Heffernan H. Mupirocin and Staphylococcus aureus: a recent paradigm of emerging antibiotic resistance. J. Antimicrob. Chemother. 2003;51:613–617
  41. Waisbren BA. Neomycin. Practitioner. 1956;176:39–46
  42. Waisbren BA. The sensitivity of staphylococci to antibiotics. A five-year study of sensitivity, usage and cross resistance in a general hospital. Arch. Intern. Med. 1958;101:397–406
  43. Walker ES, Levy F, Shorman M, David G, Abdalla J, Sarubbi FA. A decline in mupirocin resistance in methicillin-resistant Staphylococcus aureus accompanied administrative control of prescriptions. J. Clin. Microbiol. 2004;42:2792–2795
  44. Watanabe H, Masaki H, Asoh N, Watanabe K, Oishi K, Kobayashi S, et al. Low concentrations of mupirocin in the pharynx following intranasal application may contribute to mupirocin resistance in methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 2001;39:3775–3777
  45. Yun H-J, Lee SW, Yoon GM, Kim SY, Choi S, Lee YS, et al. Prevalence and mechanisms of low- and high-level mupirocin resistance in staphylococci isolated from a Korean hospital. J. Antimicrob. Chemother. 2003;51:619–623

PII: S0732-8893(05)00202-6

doi: 10.1016/j.diagmicrobio.2005.08.009

Diagnostic Microbiology & Infectious Disease
Volume 54, Issue 1 , Pages 63-71 , January 2006

Article Tools

* Image Usage & Resolution